Dr. Dulabh Monga, MD
Claim this profileAllegheny General Hospital
Studies Pancreatic Cancer
Studies Liver Cancer
10 reported clinical trials
29 drugs studied
Area of expertise
1Pancreatic Cancer
Stage III
Stage IV
BRCA1 positive
2Liver Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Dulabh Monga, MD is currently running
Atezolizumab + Multi-Kinase Inhibitor
for Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Recruiting1 award Phase 23 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Dulabh Monga, MD
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Dulabh Monga, MD has experience with
- Lenvatinib
- Irinotecan
- Nivolumab
- Ipilimumab
- Sorafenib
- Atezolizumab
Breakdown of trials Dulabh Monga, MD has run
Pancreatic Cancer
Liver Cancer
Parotid Gland Cancer
Colon Cancer
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Dulabh Monga, MD specialize in?
Is Dulabh Monga, MD currently recruiting for clinical trials?
Are there any treatments that Dulabh Monga, MD has studied deeply?
What is the best way to schedule an appointment with Dulabh Monga, MD?
What is the office address of Dulabh Monga, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.